• Citer

Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study.

par Kaufman, Bella;Trudeau, Maureen;Awada, Ahmad ;Blackwell, Kimberly;Bachelot, Thomas;Salazar, Vanessa;DeSilvio, Michelle;Westlund, Ronald;Zaks, Tal;Spector, Neil;Johnston, Stephen
Référence Lancet oncology, 10, 6, page (581-588)
Publication Publié, 2009-06

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study.
Auteur:	Kaufman, Bella; Trudeau, Maureen; Awada, Ahmad; Blackwell, Kimberly; Bachelot, Thomas; Salazar, Vanessa; DeSilvio, Michelle; Westlund, Ronald; Zaks, Tal; Spector, Neil; Johnston, Stephen
Informations sur la publication:	Lancet oncology, 10, 6, page (581-588)
Statut de publication:	Publié, 2009-06
Sujet CREF:	Sciences bio-médicales et agricoles
MeSH keywords:	Adult
	Aged
	Antineoplastic Agents -- therapeutic use
	Breast Neoplasms -- drug therapy
	Breast Neoplasms -- genetics
	Breast Neoplasms -- metabolism
	Breast Neoplasms -- mortality
	Female
	Humans
	Middle Aged
	Quinazolines -- therapeutic use
	Receptor, erbB-2 -- genetics
	Receptor, erbB-2 -- metabolism
	Recurrence
	Skin Diseases -- pathology
	Treatment Outcome
Note générale:	Clinical Trial, Phase II
	Journal Article
	Multicenter Study
	Research Support, Non-U.S. Gov't
Langue:	Anglais
Identificateurs:	urn:issn:1470-2045
	info:doi/10.1016/S1470-2045(09)70087-7
	info:pii/S1470-2045(09)70087-7
	info:scp/66149093901
	info:pmid/19394894